Relationship between the type of atrial fibrillation and thromboembolic events;Povezanost oblika atrijalne fibrilacije sa pojavom tromboembolijskih komplikacija

Vojnosanitetski Pregled

Volumn 66, Issue 11, 2009, Pages 887-891

  Potpara, Tatjana ^a   Grujić, Miodrag ^a   Vujisić Tešić, Bosiljka ^a   Ostojić, Miodrag ^a   Polovina, Marija ^a   Arandjelović, Aleksandra ^a   Mujović, Nebojča ^a  

^a CLINICAL CENTER OF SERBIA   (Serbia)

Author keywords

Atrial fibrillation; Causality; Cerebrovascular disorders; Thromboemolism

Indexed keywords

ACETYLSALICYLIC ACID;

ADULT; ARTICLE; CARDIOLOGY; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONTROLLED STUDY; DIABETES MELLITUS; DISEASE ASSOCIATION; ECHOCARDIOGRAPHY; FEMALE; FOLLOW UP; HEART ATRIUM FIBRILLATION; HEART DISEASE; HOSPITAL PATIENT; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL SPECIALIST; NEUROLOGY; OBSERVATIONAL STUDY; OUTPATIENT; OUTPATIENT DEPARTMENT; PRACTICE GUIDELINE; RISK FACTOR; SERBIA; THROMBOEMBOLISM; VASCULAR SURGERY;

EID: 73649093802     PISSN: 00428450     EISSN: None     Source Type: Journal    
DOI: 10.2298/VSP0911887P     Document Type: Article

References (17)

1. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22(8): 983-8.
2. Gage BF, Waterman AD, Shannon W, Boechler M, Rich MW, Radford MJ. Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation. JAMA 2001; 285(22): 2864-70.
3. Aboaf AP, Wolf PS. Paroxysmal atrial fibrillation. A common but neglected entity. Arch Intern Med 1996; 156(4): 362-7.
4. Hart RG, Pearce LA, Rothbart RM, McAnulty JH, Asinger RW, Halperin JL. Stroke with intermittent atrial fibrillation: incidence and predictors during aspirin therapy. Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol 2000; 35(1): 183-7. 5. Nieuwlaat R, Dinh T, Olsson SB, Camm AJ, Capucci A, Tieleman RG, et al. Euro Heart Survey Investigators. Should we abandon the common practice of withholding oral anticoagulation in paroxysmal atrial fibrillation? Eur Heart J 2008; 29(7): 915-22.
5. Fuster V, Rydén LE, Cannom DS, Crijns HJ, Curtis AB, Ellenbogen KA, et al. ACC/AHA/ESC 2006 Guidelines for the Management of Patients with Atrial Fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for Practice Guidelines (Writing Committee to Revise the 2001 Guidelines for the Management of Patients with Atrial Fibrillation). Eur Heart J 2007; 28(16): 2046.
6. Hohnloser SH, Pajitnev D, Pogue J, Healey JS, Pfeffer MA, Yusuf S, et al. Incidence of stroke in paroxysmal versus sustained atrial fibrillation in patients taking oral anticoagulation or combined antiplatelet therapy: an ACTIVE W Substudy. J Am Coll Cardiol 2007; 50(22): 2156-61.
7. Hughes M, Lip GY. Stroke and thromboembolism in atrial fibrillation: a systematic review of stroke risk factors, risk stratification schema and cost effectiveness data. Thromb Haemost 2008; 99(2): 295-304.
8. Stroke Risk in Atrial Fibrillation Working Group. Comparison of 12 risk stratification schemes to predict stroke in patients with nonvalvular atrial fibrillation. Stroke 2008; 39(6): 1901-10.
9. Fang MC, Go AS, Chang Y, Borowsky L, Pomernacki NK, Singer DE et al. ATRIA Study Group. Comparison of risk stratification schemes to predict thromboembolism in people with nonvalvular atrial fibrillation. J Am Coll Cardiol 2008; 51(8): 810-5.
10. Hart RG, Pearce LA, Aguilar MI. Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation. Ann Intern Med 2007; 146(12): 857-67.
11. Odén A, Fahlén M, Hart RG. Optimal INR for prevention of stroke and death in atrial fibrillation: a critical appraisal. Thromb Res 2006; 117(5): 493-9.
12. Fang MC, Go AS, Chang Y, Hylek EM, Henault LE, Jensvold NG, et al. Death and disability from warfarin-associated intracranial and extracranial hemorrhages. Am J Med 2007; 120(8): 700-5.
13. Go AS, Hylek EM, Chang Y, Phillips KA, Henault LE, Capra AM, et al. Anticoagulation therapy for stroke prevention in atrial fibrillation: how well do randomized trials translate into clinical practice? JAMA 2003; 290(20): 2685-92.
14. Willems R, Exner DV. Do population studies confirm the benefit of oral anticoagulation in atrial fibrillation demonstrated in clinical trials? J Interv Card Electrophysiol 2004; 10 Suppl 1: 9-16.
15. Nieuwlaat R, Capucci A, Lip GY, Olsson SB, Prins MH, Nieman FH, et al. Antithrombotic treatment in real-life atrial fibrillation patients: a report from the Euro Heart Survey on Atrial Fibrillation. Eur Heart J 2006; 27(24): 3018-26.
16. Friberg L, Hammar N, Ringh M, Pettersson H, Rosenqvist M. Stroke prophylaxis in atrial fibrillation: who gets it and who does not? Report from the Stockholm Cohort-study on Atrial Fibrillation (SCAF-study). Eur Heart J 2006; 27(16): 1954-64.
17. Rowan SB, Bailey DN, Bublitz CE, Anderson RJ. Trends in anticoagulation for atrial fibrillation in the U.S.: an analysis of the national ambulatory medical care survey database. J Am Coll Cardiol 2007; 49(14): 1561-5.